Side-by-side · Research reference

SemaglutidevsTestagen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AFDA-ApprovedFlagship15/53 cited

BAnimal-MechanisticHUMAN-REVIEWED11/41 cited

Semaglutide

GLP-1 RA · FDA-Approved

0.25–2.4 mgWeekly doseWEGOVY (semaglutide) injection 2021

14.9%Body-weight ↓Wilding 2021

~7 daysHalf-lifeWEGOVY (semaglutide) injection 2021

SQ · Abdomen / thigh / arm · Once weekly

Testagen

Bioregulator Peptide · Khavinson School

Lys-Glu-Asp-GlySequenceFedoreyeva 2011

NuclearLocalizationFedoreyeva 2011

TesticularTissue target

SQ · Abdomen · Cyclical

01Mechanism of Action

Parameter

Semaglutide

Testagen

Primary target

GLP-1 receptor (GLP-1R)WEGOVY (semaglutide) injection 2021

Testicular tissue; proposed nuclear DNA interaction

Pathway

GLP-1R agonism → ↑glucose-dependent insulin secretion, ↓glucagon, ↓gastric emptying, ↓appetite via hypothalamic centresWilding 2021

Nuclear penetration → DNA/oligonucleotide binding → gene expression modulation (bioregulator hypothesis)Fedoreyeva 2011

Downstream effect

Improved glycemic control, reduced caloric intake, body-weight reduction, cardiovascular risk reductionWilding 2021

Proposed support for spermatogenesis and testicular function; mechanistic data limited to nuclear localization and DNA interactionFedoreyeva 2011

Feedback intact?

Glucose-dependent insulin release preserves physiological feedback

Unknown — no HPG axis data

Origin

Modified GLP-1(7-37) with two amino-acid substitutions and C-18 fatty-acid acylation for albumin binding and 168-h half-lifeWEGOVY (semaglutide) injection 2021

Khavinson bioregulator school — isolated from testicular tissue peptide fractions

Antibody development

—

02Dosage Protocols

Parameter

Semaglutide

Testagen

Standard dose (T2D, Ozempic)

0.5–1.0 mg / weekWEGOVY (semaglutide) injection 2021

—

Standard dose (weight, Wegovy)

2.4 mg / week (after 16-wk titration)WEGOVY (semaglutide) injection 2021 Wilding 2021

—

Frequency

Once weekly, same day each week

Once daily or alternate days

Titration schedule

0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over 16 weeks

Mitigates GI side effects.

—

Evidence basis

FDA-approved · Phase 3 RCTsWilding 2021 WEGOVY (semaglutide) injection 2021

Animal mechanistic / in vitro onlyFedoreyeva 2011

Duration

Indefinite for chronic indication

Discontinuation results in weight regain.

—

Reconstitution

Pre-mixed pen device (commercial). Research lyophilised vial: bacteriostatic water per label.

Sterile water or bacteriostatic saline

Timing

Any time of day, with or without food

—

Half-life

~7 days (168 h)WEGOVY (semaglutide) injection 2021

Unknown — likely minutes (short peptide)

Typical protocol (anecdotal)

—

100–200 mcg / day

No published human dosing studies; derived from Russian bioregulator practice.

Cycle length

—

10–20 days on, 10–14 days off

Bioregulator tradition uses pulsed cycles; no controlled data.

Route

—

Subcutaneous

04Side Effects & Safety

Parameter

Semaglutide

Testagen

GI symptoms

Nausea, vomiting, diarrhea, constipation (very common)Wilding 2021

—

Injection site reaction

Mild erythema, pruritus

—

Pancreatitis risk

Rare; discontinue if suspectedWEGOVY (semaglutide) injection 2021

—

Thyroid C-cell tumours

Boxed warning — contraindicated in MEN2 / personal or family MTC historyWEGOVY (semaglutide) injection 2021

—

Hypoglycemia

Low risk as monotherapy; elevated when combined with sulfonylureas / insulin

—

Gallbladder events

Increased cholelithiasis

—

Pregnancy / OB

ContraindicatedWEGOVY (semaglutide) injection 2021

—

Heart rate

Modest ↑ resting HR (~2-4 bpm)

—

Injection site reactions

—

Erythema, mild irritation (potential)

Systemic effects

—

Unknown — no human safety data

Hormonal impact

—

No published data on testosterone, LH, FSH effects

Long-term safety

—

Unknown — no long-term studies

Absolute Contraindications

Semaglutide

·Personal or family history of medullary thyroid carcinoma
·Multiple endocrine neoplasia syndrome type 2
·Pregnancy / breastfeeding
·Hypersensitivity to semaglutide

Testagen

·Active testicular malignancy

Relative Contraindications

Semaglutide

·Severe gastroparesis
·History of pancreatitis
·Diabetic retinopathy (may worsen with rapid glycemic improvement)

Testagen

·Hormone-sensitive cancers (no data; theoretical caution)
·Pregnant or breastfeeding (no data)

05Administration Protocol

Parameter

Semaglutide

Testagen

1. Reconstitution / device

Commercial: pre-filled pen, no reconstitution. Research vial: per-label or bacteriostatic water.

Add 1–2 mL sterile or bacteriostatic water to lyophilised vial. Swirl gently; do not shake. Solution should be clear.

2. Injection site

SQ — abdomen, thigh, or upper arm. Rotate sites weekly to avoid lipohypertrophy.

Subcutaneous — abdomen or thigh. Rotate sites daily. Use standard insulin syringe (27–31G).

3. Timing

Once weekly, same day. Day can be changed if ≥2 days separate doses.

Morning or evening; no established optimal timing. Anecdotal preference: evening to align with circadian testosterone patterns.

4. Storage

Pen: refrigerate 2–8 °C unopened; room temp ≤30 °C up to 56 days after first use.

Lyophilised: room temp, dark. Reconstituted: refrigerate 2–8 °C, use within 14–21 days if bacteriostatic water used.

5. Needle

Pen-supplied 31–34G needle. Research vial: 27–31G insulin syringe.

10–20 days on, 10–14 days off. Bioregulator tradition uses pulsed exposure; rationale: prevent receptor/pathway desensitisation.

06Stack Synergy

Semaglutide

+ Tirzepatide

Weak

View Tirzepatide →

Combining two GLP-1 RA-class drugs is not clinically validated and risks additive GI toxicity. Tirzepatide's GIP component already provides complementary mechanism vs pure GLP-1; stacking with semaglutide adds receptor saturation but no synergy. NOT recommended.

Note: Stack not recommended — choose one GLP-1 RA
Primary benefit: (none — additive toxicity, no synergy)

Testagen

— no documented stacks